Jasper Therapeutics Announces That It Is Commencing An Open-Label Extension Study In Chronic Urticarias That Will Roll Over Patients From The BEACON And SPOTLIGHT Studies Upon Completion Of Their Initial Follow Up Period
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics (NASDAQ:JSPR) is starting an open-label extension study for chronic urticarias, rolling over patients from the BEACON and SPOTLIGHT studies. They have regulatory clearance to expand the BEACON study with a new 360mg dose cohort, with data expected in early 2025.
October 23, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jasper Therapeutics is advancing its clinical trials for briquilimab, targeting chronic urticarias. The company has regulatory clearance to expand its BEACON study, which could enhance its drug development pipeline.
The announcement of an open-label extension study and regulatory clearance for expanding the BEACON study indicates progress in Jasper's drug development. This could positively impact investor sentiment and the stock price, especially if upcoming data is favorable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100